Racial differences in the outcome of patients with urothelial carcinoma of the upper urinary tract: an international study

Kazumasa Matsumoto¹, Giacomo Novara², Amit Gupta³, Vitaly Margulis³⁴, Thomas J. Walton⁵, Marco Roscigno⁶, Casey Ng⁷, Eiji Kikuchi⁸, Richard Zigeuner⁹, Wassim Kassouf¹⁰, Hans-Martin Fritsche¹¹, Vincenzo Ficarra², Guido Martignoni¹², Stefan Tritschler¹³, Joaquin Carballido Rodriguez¹⁴, Christian Seitz¹⁵, Alon Weizer¹⁶, Mesut Remzi¹⁷, Jay D. Raman⁷, Christian Bölenz¹⁸, Karim Bensalah¹⁹, Theresa M. Koppie²⁰, Pierre I. Karakiewicz²¹, Christopher G. Wood⁴, Francesco Montorsi⁶, Masatsugu Iwamura¹ and Shahrokh F. Shariat²²

¹Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan; ²University of Padua, Padua, Italy; ³University of Texas, Southwestern Medical Center, Dallas, TX, ⁴University of Texas MD Anderson Cancer Center, Houston, TX, USA; ⁵Royal Derby Hospital, Derby, UK; ⁶Vita-Salute University, Milan, Italy; ⁷Division of Urology, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA; ⁸Keio University School of Medicine, Tokyo, Japan; ⁹Medical University Graz, Graz, Austria; ¹⁰McGill University Health Centre, Montréal, Quebec, Canada; ¹¹Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany; ¹²University of Verona, Verona, Italy; ¹³Ludwig-Maximilians-University, Klinikum Grosshadern, Munich, Germany; ¹⁴Hospital Universitario Puerta de Hierro-Majadahonda, Universidad Autónoma de Madrid, Madrid, Spain; ¹⁵General Hospital Bolzano, Bolzano, Italy; ¹⁶University of Michigan, Ann Arbor, MI, USA; ¹⁷Medical University of Vienna, Vienna, Austria; ¹⁸Mannheim Medical Center, University of Heidelberg, Germany; ¹⁹University of Rennes, Rennes, France; ²⁰University of California Davis, Sacramento, CA, USA; ²¹University of Montréal, Montréal, Quebec, Canada; ²²Weill Medical College of Cornell University, New York, NY, USA

Accepted for publication 26 November 2010

K.M. and G.N. equally contributed to the study.

What’s known on the subject? and What does the study add?
The differential effect of ethnicity on clinico-pathological features and cancer-related outcomes remains uninvestigated in upper tract urothelial carcinoma.
Ethnicity was not an independent predictor of either recurrence or cancer-related death in upper tract urothelial carcinoma.

OBJECTIVE
To assess the impact of differences in ethnicity on clinico-pathological characteristics and outcomes of patients with upper urinary tract urothelial carcinoma (UTUC) in a large multi-center series of patients treated with radical nephroureterectomy (RNU).

MATERIALS AND METHODS
We retrospectively collected the data of 2163 patients treated with RNU at 20 academic centres in America, Asia, and Europe.
Univariable and multivariable Cox regression models addressed recurrence-free survival (RFS) and cancer-specific survival (CSS).

RESULTS
In all, 1794 (83%) patients were Caucasian and 369 (17%) were Japanese. All the main clinical and pathological features were significantly different between the two ethnicities.
The median follow-up of the whole cohort was 36 months. At last follow-up, 554 patients (26%) developed disease recurrence and 461 (21%) were dead from UTUC.
The 5-year RFS and CSS estimates were 71.5% and 74.2%, respectively, for Caucasian patients compared with 68.8% and 75.4%, respectively, for Japanese patients.
On univariable Cox regression analyses, ethnicity was not significantly associated with either RFS (P = 0.231) or CSS (P = 0.752).
• On multivariable Cox regression analyses that adjusted for the effects of age, gender, surgical type, T stage, grade, tumour architecture, presence of concomitant carcinoma in situ, lymphovascular invasion, tumour necrosis, and lymph node status, ethnicity was not associated with either RFS (hazard ratio [HR] 1.1; \( P = 0.447 \)) or CSS (HR 1.0; \( P = 0.908 \)).

CONCLUSIONS

• There were major differences in the clinico-pathological characteristics of Caucasian and Japanese patients.
• However, RFS and CSS probabilities were not affected by ethnicity and race was not an independent predictor of either recurrence or cancer-related death.

KEYWORDS

race, prognosis, urinary tract cancer, urothelial carcinoma, nephroureterectomy, recurrence

INTRODUCTION

The incidence of cancer and its biological behaviour varies considerably among ethnicities and between geographic areas [1–3]. For example, epidemiological studies originating from the USA show that tumour stage and mortality rates for many cancers including those arising from breast, colon and rectum, kidney, prostate, and lung are highest in African-Americans followed by Whites and are lowest in Asians/Pacific Islanders [4–6]. Similarly, for bladder urothelial carcinoma (UC), African-Americans have worse overall survival when compared with Caucasian patients [7–10]. Although much of this difference has been attributed to higher stage at presentation in African-Americans [8,9], outcome disparities still persist after controlling for tumour stage, grade, treatment effect, and other cause mortality [10]. Potential differences contributing to these disparities among ethnicities and geographic locations include delays in presentation/diagnosis, inherent biological behaviour of the tumour, socioeconomic status, lack of adequate health care access, differences in exposure to environmental risk factors such as smoking, and social support. For upper urinary tract UC (UTUC), to our knowledge, the differential effect of ethnicity on clinico-pathological features and cancer-related outcomes remains uninvestigated.

Therefore, the purpose of the present study was to assess the effect of differences in ethnicity on clinico-pathological characteristics and outcomes of patients with UTUC in a large multi-center series of patients treated with radical nephroureterectomy (RNU) in three continents [America, Asia, and Europe], encompassing nine countries (USA, Canada, Japan, Austria, France, England, Germany, Italy, and Spain).

PATIENTS AND METHODS

This was an Institutional Review Board-approved study with all participating sites providing the necessary institutional data sharing agreements before initiation of the study. In all, 20 academic centres worldwide provided data. A computerized databank was generated for data transfer. After combining the datasets, reports were generated for each variable to identify data inconsistencies and other data integrity problems. Through regular communication with all sites, resolution of all identified anomalies was achieved before analysis. Before final analysis, the database was frozen, and the final data set was produced for the present analysis.

The database comprised 2217 patients who underwent RNU with ipsilateral bladder cuff resection between 1987 and 2008. After exclusion of patients in whom ethnicity was unknown (six patients), and of the few patients that were African-American (27) or Hispanic (21), the 2163 patients left were the subjects of the present analysis.

Surgery was performed by several surgeons according to the standard criteria for RNU, i.e. extrafascial dissection of the kidney with the entire length of ureter and adjacent segment of the bladder cuff. The hilar and regional LNs adjacent to the ipsilateral great vessel generally were resected together with enlarged LNs if abnormal on preoperative CT or palpable intraoperatively. Extended lymphadenectomy was not routinely performed.

All surgical specimens were processed according to standard pathological procedures at each institution. Tumours were staged according to the American Joint Committee on Cancer–Union Internationale Contre le Cancer TNM classification [11]. Tumour grading was assessed according to the 1998 WHO/International Society of Urologic Pathology consensus classification [12].

Patients were generally followed-up every 3–4 months for the first year after RNU, every 6 months from the second through to the fifth year, and annually thereafter. Follow-up consisted of a history, physical examination, routine blood work and serum chemistry studies, urinary cytology, chest radiography, cystoscopic evaluation of the urinary bladder, and radiographic evaluation of the contralateral upper urinary tract. Elective bone scan, chest CT, and MRI were performed when clinically indicated.

Disease recurrence was defined as local failure in the operative site, regional LNs, or distant metastasis. Bladder recurrences were not considered in the analysis of the recurrence-free survival (RFS) rate. Cause of death was determined by the treating physicians, by chart review corroborated by death certificates, or by death certificates alone. Most patients who were identified as having died from UTUC had progressive, widely disseminated metastases at the time of death. Patients who died in the perioperative period (i.e. death within 30 days of surgery) were censored at time of death for cancer-specific survival (CSS) analyses.

The Fisher’s exact test and the chi-square test were used to evaluate the association between categorical variables. Differences in variables with a continuous distribution across dichotomous categories were assessed using the Mann–Whitney U-test. The Kaplan–Meier method was used to calculate survival functions, and differences were assessed with the log-rank statistic. Univariable and multivariable Cox regression models addressed time to recurrence and cancer-specific mortality after RNU. Statistical significance in this study was set as \( P \leq 0.05 \). All reported \( P \) values are two-sided.
RESULTS

ASSOCIATION OF ETHNICITY WITH CLINICAL AND PATHOLOGICAL FEATURES

In all, 1794 (83%) patients were Caucasian and 369 (17%) were Japanese. Table 1 shows the association of clinical and pathological features with ethnicity. Patients’ age, gender, tumour stage, tumour grade, prevalence of lymphovascular invasion, tumour architecture, prevalence of tumour necrosis, presence of concomitant carcinoma in situ (CIS), and use of adjuvant chemotherapy were significantly different between the two ethnicities (all \( P < 0.05 \)). Moreover, also follow-up duration from RNU was slightly longer in Japanese patients (\( P = 0.039 \)).

ASSOCIATION OF RACE WITH CLINICAL OUTCOMES

The median (interquartile range, IQR) follow-up of the whole cohort was 36 (15.3–71.1) months. At last follow-up, 554 patients (26%) had developed disease recurrence and 461 (21%) were dead from UTUC. Moreover, 301 (14%) had noncancer-related deaths. The median (IQR) follow-up for patients alive at last follow-up was 45 (20–81) months. At last follow-up, 554 patients (26%) were alive, 224 (10%) were deceased from UTUC. Moreover, 301 (14%) had noncancer-related deaths. The median (IQR) follow-up duration from RNU was slightly longer in Japanese patients (\( P = 0.23 \) for RFS and 0.75 for CSS).

The 5- and 10-year RFS estimates were 71% (standard error, SE = 1.1%) and 67% (SE = 1.3%) respectively. The overall 5- and 10-year CSS estimates were 74.4% (SE = 1.1%) and 69.1% (SE = 1.4%), respectively.

The 5-year RFS and CSS rates were 71.5% (SE = 1.2%) and 74.2% (SE = 1.2%), respectively, for Caucasian patients compared with 68.8% (SE = 2.7%) and 75.4% (SE = 2.6%), respectively, for Japanese patients (Fig. 1A,B, respectively; \( P \) value 0.23 for RFS and 0.75 for CSS).

Re-analysis of the data after exclusion of 224 patients who received adjuvant chemotherapy yielded consistent statistical patterns (data not shown).

DISCUSSION

In the present multi-institutional study involving about 2200 patients with UTUC...
undergoing RNU there were major differences in the clinico-pathological characteristics of Caucasian and Japanese patients. However, RFS and CSS probabilities were not affected by ethnicity and race was not an independent predictor of either recurrence or cancer-related death, once adjusted for the effects of other clinical and pathological covariates.

It is well established by epidemiological studies that rates of cancers incidence and deaths vary considerably among racial groups. Data from the National Center for Health Statistics concerning statistics collected from 1930 to 2006 in the USA showed that African-Americans had incidence and death rates that were consistently higher than in Whites for all cancer sites, excluding breast, lung and kidney cancers [4,5]. Specifically, all site incidence and mortality rates were 651.5 and 313 per 100 000 in male African-Americans and 389 and 230.7 per 100 000 in female African-Americans, respectively, compared with 551.4 and 230.7 per 100 000 in male White and with 423.6 and 159.2 per 100 000 in female White, respectively. Significantly lower figures, indeed, were shown for Asian-American and Hispanic, compared with both African-American and White [4].

However, specific epidemiological data for UTUC are missing, due to the low prevalence of the disease and, above all, to the lack of a specific code able to distinguish RCC and renal pelvis UTUC in the International Classification of Diseases. However, figures for bladder UC reconfirmed a similar trend, with significantly higher incidence and mortality rates in White patients (22.8 and 4.6 per 100 000, respectively), compared with African-American (12.8 and 3.7 per 100 000, respectively), Asian-American (9.3 and 1.7 per 100 000, respectively), and Hispanic patients (11.4 and 2.4 per 100 000, respectively) [6]. In the present analysis, there was a high prevalence of non-organ confined (43%) and high-grade (82%) disease in Asiatic patients, which is in agreement with previous report from Taiwan [13,14], where pT3–4 disease might be as frequent as 50%. Several hypotheses can be made to explain the differences in the clinical and pathological characteristics of UTUC at presentation. For example, environmental and occupational exposures, lifestyle choices such as smoking and nutrition, and socioeconomic and cultural factors involving access to and the willingness to seek care may account for such differences [15]. However, despite the large number of patients, we were unable to find any statistically significant differences in RFS and CSS probabilities, between these two racial groups. Moreover, the few African-American and Hispanic patients in our dataset prevented us from including them in the analysis.

For the other predictors of RFS and CSS, in our multivariable models we showed that patients’ age at surgery, pathological stage of the primary tumour, tumour grade, presence of lymphovascular invasion, tumour architecture, and LN stage were independent predictors of both recurrence and survival, while type of surgery was significantly associated only with cancer-related death. The data of the present study reproduced and validated those previously available on pT stage and grade [16,17], lymphovascular invasion [18,19], architecture [20], and LN stage [21]. Notably, patients undergoing laparoscopic RNU had worse CSS once adjusted for the effects of the other covariates. The data echoes the findings of

FIG. 1. Kaplan–Meier curves of RFS and CSS stratified by patients’ race in 2163 patients treated with RNU and ipsilateral bladder-cuff excision for UTUC. Green, Caucasian patients; blue, Japanese patients. Log-rank P values 0.23 for RFS and 0.75 for CSS.
Simone et al. [22], who showed that laparoscopic surgery may jeopardize the outcome of patients with locally advanced disease. However, similar data were not reproduced in large multi-institutional comparative studies [23,24].

There are several limitations to the present study. First and foremost are the limitations inherent to retrospective analyses. Although we have done multiple internal and external reviews of our consortium dataset, we excluded from this analysis patients for whom we could not obtain complete information, which could possibly create selection bias. In addition, the population in this study underwent RNU by multiple surgeons, indication and extension of LN dissection were not standardized, and the follow-up lacked uniformity. However, all surgeons operated at selected centres with significant experience in UC management, which might increase the external validity of the data, compared with the single-centre, single-surgeon setting. Similarly, whereas it may be preferable for a single pathologist specialized in genitourinary pathology to review each specimen, the multi-centric nature of the present study and the use of institutional pathological interpretation possibly make the results more relevant in the daily clinical setting. Nevertheless, all specimens were examined by dedicated genitourinary pathologists at selected centres. Another limitation is that there were few Hispanic and African-American patients, which prevented us from drawing conclusions on these racial groups. In addition we did not control for important factors such as patient comorbidity, socioeconomic status, marital status and other measures of social support, body mass index, and smoking status, which have been shown to be of interest in some reports [25–27].

In conclusion, there were major differences in the clinico-pathological characteristics of Caucasian and Japanese patients. However, RFS and CSS probabilities were not affected by ethnicity and race was not an independent predictor of either recurrence or cancer-related death, once adjusted for the effects of other clinical and pathological covariates. In terms of racial differences of biological behaviour, future research is warranted to take into account the components, including environmental and occupational exposures, lifestyle choices, socioeconomic, cultural and genetic factors.
CONFLICT OF INTEREST

None declared.

REFERENCES

1 Aben KK, Kiemeney LA. Epidemiology of bladder cancer. Eur Urol 1999; 36: 660–72
21 Roscigno M, Shariat SF, Margulis V et al. The extent of lymphadenectomy seems to be associated with better survival in patients with nonmetastatic upper-tract urothelial carcinoma: how many lymph nodes should be removed? Eur Urol 2009; 56: 512–8

Abbreviations: (UT)UC, (upper urinary tract) urothelial carcinoma; RNU, radical nephroureterectomy; RFS, recurrence-free survival; CSS, cancer-specific survival; CIS, carcinoma in situ; IQR, interquartile range; SE, standard error; LN, lymph node; HR, hazard ratio.